Trials / Unknown
UnknownNCT04677088
TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation
Phase I Study of T Cell Receptor-Redirected T Cells With Recurrent HBV Treatment in Patients-Related Hepatocellular Carcinoma in Post Liver Transplantation
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Xiaoshun He · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm and open-label study to assess the safety, tolerability and primary efficacy of the HBV specific T cell receptor (HBV/TCR) redirected T cell in patients with recurrent Hepatitis B virus (HBV) related hepatocellular carcinoma post liver transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TCR-T cells | Patients will receive 1 x 10\^4 cells/kg to 5 x 10\^6 cells/kg bodyweight of TCR redirected T cells by IV infusion. |
Timeline
- Start date
- 2018-03-29
- Primary completion
- 2020-02-18
- Completion
- 2021-12-01
- First posted
- 2020-12-21
- Last updated
- 2020-12-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04677088. Inclusion in this directory is not an endorsement.